menu
    • menu

    Company profile for Aarti Pharmalabs

    Aarti Pharmalabs-PSE
    News
    Aarti Pharmalabs achieves SBTi approval of GHG emission reduction

    22 Apr 2025

    // PRESS RELEASE

    Aarti Pharmalabs gets SBTi approval for GHG reduction targets

    17 Apr 2025

    // PRESS RELEASE

    Audited Financial Results for the Quarter ended 30th June, 2024

    05 Aug 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Aarti Industries RMU

    Contact Supplier

    Website

    AACR Annual meeting

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.youtube.com/embed/w_0eQJQLaHk

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Related CompaniesRelated Companies

    About

    Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cytotoxic & oncology products. It has 2 R&D centers & 3 cGMP plants successfully audited by the USFDA, EUGMP, EDQM, KFDA & COFEPRIS. It offers CDMO services for generic APIs & NCEs, intermediates & key building blocks.

    Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aarti Pharmalabsindia-flag Flag
    Country
    Country
    India
    Address
    Address
    Embassy Park 247, Tower C, 401, 4th Floor, LBS Marg, Vikhroli (W), Mumbai
    Telephone
    Telephone
    +91 2269436100
    Client Email
    Email
    api@aartipharmalabs.com
    Client Website
    Website
    https://www.aartipharmalabs.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aarti-pharmalabs-limited
    youtube
    YouTube
    https://www.youtube.com/@aartipharmalabs-sj3zo
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/aarti-pharmalabs-party-content-21253.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/aarti-industries-party-content-1632804508.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/aarti-pharmalabs-party-content-38919.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediates Product List 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/aarti-pharmalabs-party-content-14380.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2019

    read-more

      https://www.pharmacompass.com/pdf/party/content/aarti-industries-party-content-1633683447.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 2958

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

    Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397  Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17   13 37 Taiwan 9 6 5 4 24 Switzerland 15 4   4 23 France 16     6 22 Japan 18   1   19 United Kingdom 12 1   2 15 Mexico 9 1   1 11 Ireland 5 5   1 11   Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 13355

    https://www.pharmacompass.com/radio-compass-blog/chinese-fda-registered-generic-facilities-gain-steam-india-maintains-lead-with-396-facilities

    #PharmaFlow by PHARMACOMPASS
    21 Nov 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3647

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Aarti Pharmalabs achieves SBTi approval of GHG emission reduction
    Aarti Pharmalabs achieves SBTi approval of GHG emission reduction

    22 Apr 2025

    // PRESS RELEASE

    https://www.aartipharmalabs.com/aarti-pharmalabs-imited-achieves-key-sustainability-milestone

    PRESS RELEASE
    22 Apr 2025
    Share Share
    Aarti Pharmalabs gets SBTi approval for GHG reduction targets
    Aarti Pharmalabs gets SBTi approval for GHG reduction targets

    17 Apr 2025

    // PRESS RELEASE

    https://www.aartipharmalabs.com/aarti-pharmalabs-imited-achieves-key-sustainability-milestone

    PRESS RELEASE
    17 Apr 2025
    Share Share
    Audited Financial Results for the Quarter ended 30th June, 2024
    Audited Financial Results for the Quarter ended 30th June, 2024

    05 Aug 2024

    // PRESS RELEASE

    https://www.aartipharmalabs.com/investors/audited-financial-statements-for-the-quarter-ended-june-30-2024.pdf

    PRESS RELEASE
    05 Aug 2024
    Share Share
    Business Responsibility and Sustainability Report
    Business Responsibility and Sustainability Report

    15 Jul 2024

    // PRESS RELEASE

    https://www.aartipharmalabs.com/investors/apl-brsr-2024.pdf

    PRESS RELEASE
    15 Jul 2024
    Share Share
    Aarti Pharmalabs Annual Report 2023-24
    Aarti Pharmalabs Annual Report 2023-24

    15 Jul 2024

    // PRESS RELEASE

    https://www.aartipharmalabs.com/investors/annual-report-2023-24.pdf

    PRESS RELEASE
    15 Jul 2024
    Share Share
    Aarti Pharmalabs jumps after Q4 PAT climbs 52% YoY to Rs 65 cr
    Aarti Pharmalabs jumps after Q4 PAT climbs 52% YoY to Rs 65 cr

    14 May 2024

    // BUSINESS-STANDARD

    https://www.business-standard.com/markets/capital-market-news/aarti-pharmalabs-jumps-after-q4-pat-climbs-52-yoy-to-rs-65-cr-124051400192_1.html

    BUSINESS-STANDARD
    14 May 2024
    Share Share

    CEP/COS

    read-more
    read-more

    01

    Adapalene

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : CEP 2022-158 - Rev 00

    Status : Valid

    Issue Date : 2024-06-19

    Type : Chemical

    Substance Number : 2445

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Azathioprine, Process 2

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2014-030 - Rev 01

    Status : Valid

    Issue Date : 2022-10-20

    Type : Chemical

    Substance Number : 369

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Benazepril hydrochloride

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2011-197 - Rev 00

    Status : Valid

    Issue Date : 2018-05-16

    Type : Chemical

    Substance Number : 2388

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Benazepril hydrochloride, Process 2

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R0-CEP 2023-055 - Rev 00

    Status : Valid

    Issue Date : 2023-07-07

    Type : Chemical

    Substance Number : 2388

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Bicalutamide

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2012-223 - Rev 01

    Status : Valid

    Issue Date : 2022-11-21

    Type : Chemical

    Substance Number : 2196

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Budesonide

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2006-295 - Rev 04

    Status : Valid

    Issue Date : 2022-10-14

    Type : Chemical

    Substance Number : 1075

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Deferiprone

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : CEP 2024-124 - Rev 00

    Status : Valid

    Issue Date : 2024-10-09

    Type : Chemical

    Substance Number : 2236

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Fluticasone propionate

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2007-262 - Rev 03

    Status : Valid

    Issue Date : 2022-10-14

    Type : Chemical

    Substance Number : 1750

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Formoterol fumarate dihydrate

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2013-220 - Rev 02

    Status : Valid

    Issue Date : 2022-10-20

    Type : Chemical

    Substance Number : 1724

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Ipratropium bromide

    India
    arrow
    AACR Annual meeting
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.

    Aarti Pharmalabs

    Certificate Numbers : R1-CEP 2008-150 - Rev 03

    Status : Valid

    Issue Date : 2022-10-14

    Type : Chemical

    Substance Number : 919

    Aarti Industries Company Banner

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Aarti Pharmalabs and get a quotation

    Aarti Pharmalabs is a supplier offers 75 products (APIs, Excipients or Intermediates).

    Find a price of Adapalene bulk with DMF, CEP, JDMF, WC offered by Aarti Pharmalabs

    Find a price of Bicalutamide bulk with DMF, CEP, JDMF, WC offered by Aarti Pharmalabs

    Find a price of Salmeterol Xinafoate bulk with DMF, CEP, JDMF, WC offered by Aarti Pharmalabs

    Find a price of Venlafaxine Hydrochloride bulk with DMF, CEP, JDMF, WC offered by Aarti Pharmalabs

    Find a price of Azathioprine bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Benazepril Hydrochloride bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Budesonide bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Deferiprone bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Fluticasone Propionate bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Ipratropium Bromide bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Mercaptopurine bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Mesna bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Mometasone Furoate bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Quetiapine Hemifumarate bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Quinapril bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Ramipril bulk with DMF, CEP, WC offered by Aarti Pharmalabs

    Find a price of Apixaban bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Benazepril Hydrochloride bulk with DMF, CEP offered by Aarti Pharmalabs

    Find a price of Bupropion Hydrochloride bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Capecitabine bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Ciclesonide bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Cyclophosphamide bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Desonide bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Diflunisal bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Enzalutamide bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Fluticasone Furoate bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Formoterol Fumarate bulk with CEP, WC offered by Aarti Pharmalabs

    Find a price of Ifosfamide bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Levalbuterol Hydrochloride bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Loteprednol Etabonate bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Perindopril Erbumine bulk with CEP, WC offered by Aarti Pharmalabs

    Find a price of Ranolazine bulk with DMF, WC offered by Aarti Pharmalabs

    Find a price of Venlafaxine Hydrochloride bulk with DMF, CEP offered by Aarti Pharmalabs

    Find a price of Acalabrutinib bulk with DMF offered by Aarti Pharmalabs

    Find a price of Bambuterol Hydrochloride bulk with WC offered by Aarti Pharmalabs

    Find a price of Benazepril bulk with DMF offered by Aarti Pharmalabs

    Find a price of Cinacalcet Hydrochloride bulk with WC offered by Aarti Pharmalabs

    Find a price of Cyclophosphamide bulk with DMF offered by Aarti Pharmalabs

    Find a price of Elagolix Sodium bulk with DMF offered by Aarti Pharmalabs

    Find a price of Empagliflozin bulk with DMF offered by Aarti Pharmalabs

    Find a price of Fluticasone Furoate bulk with WC offered by Aarti Pharmalabs

    Find a price of Lacidipine bulk with WC offered by Aarti Pharmalabs

    Find a price of Mometasone Furoate bulk with DMF offered by Aarti Pharmalabs

    Find a price of Nilotinib bulk with WC offered by Aarti Pharmalabs

    Find a price of Perindopril Arginine bulk with WC offered by Aarti Pharmalabs

    Find a price of Perindopril Erbumine bulk with WC offered by Aarti Pharmalabs

    Find a price of Phenylephrine Hydrochloride bulk with WC offered by Aarti Pharmalabs

    Find a price of Sitagliptin Hydrochloride bulk with WC offered by Aarti Pharmalabs

    Find a price of Sitagliptin Phosphate bulk with WC offered by Aarti Pharmalabs

    Find a price of Venetoclax bulk with DMF offered by Aarti Pharmalabs

    Find a price of Adapalene bulk offered by Aarti Pharmalabs

    Find a price of Aminophylline bulk offered by Aarti Pharmalabs

    Find a price of Apalutamide bulk offered by Aarti Pharmalabs

    Find a price of Apremilast bulk offered by Aarti Pharmalabs

    Find a price of Bicalutamide bulk offered by Aarti Pharmalabs

    Find a price of Caffeine bulk offered by Aarti Pharmalabs

    Find a price of Canagliflozin bulk offered by Aarti Pharmalabs

    Find a price of Dapagliflozin bulk offered by Aarti Pharmalabs

    Find a price of Edoxaban Tosylate bulk offered by Aarti Pharmalabs

    Find a price of Enalapril Maleate bulk offered by Aarti Pharmalabs

    Find a price of Etofylline bulk offered by Aarti Pharmalabs

    Find a price of Formoterol Fumarate bulk offered by Aarti Pharmalabs

    Find a price of Ibrutinib bulk offered by Aarti Pharmalabs

    Find a price of Mirabegron bulk offered by Aarti Pharmalabs

    Find a price of Montelukast Sodium bulk offered by Aarti Pharmalabs

    Find a price of Olaparib bulk offered by Aarti Pharmalabs

    Find a price of Osimertinib Mesylate bulk offered by Aarti Pharmalabs

    Find a price of Palbociclib bulk offered by Aarti Pharmalabs

    Find a price of Ribociclib bulk offered by Aarti Pharmalabs

    Find a price of Rivaroxaban bulk offered by Aarti Pharmalabs

    Find a price of Ruxolitinib Phosphate bulk offered by Aarti Pharmalabs

    Find a price of Salbutamol Sulphate bulk offered by Aarti Pharmalabs

    Find a price of Theophylline bulk offered by Aarti Pharmalabs

    Find a price of Ticagrelor bulk offered by Aarti Pharmalabs

    Find a price of Tofacitinib Citrate bulk offered by Aarti Pharmalabs

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search